Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Primary research

Promotion of tumor development in prostate cancer by progerin

Authors: Yong Tang, Yakun Chen, Hongmei Jiang, Daotai Nie

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Progerin is a truncated form of lamin A. It is identified in patients with Hutchinson-Gilford progeria syndrome (HGPS), a disease characterized by accelerated aging. The contribution of progerin toward aging has been shown to be related to increased DNA damages. Since aging is one major risk factor for carcinogenesis, and genomic instability is a hallmark of malignant cancers, we investigated the expression of progerin in human cancer cells, and whether its expression contributes to carcinogenesis. Using RT-PCR and Western blotting, we detected the expression of progerin in prostate PC-3, DU145 and LNCaP cells at mRNA and protein levels. Ectopic progerin expression did not cause cellular senescence in PC-3 or MCF7 cells. PC-3 cells progerin transfectants were sensitized to DNA damage agent camptothecin (CPT); and persistent DNA damage responses were observed, which might be caused by progerin induced defective DNA damage repair. In addition, progerin transfectants were more tumorigenic in vivo than vector control cells. Our study for the first time describes the expression of progerin in a number of human cancer cell lines and its contributory role in tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M: Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003, 300 (5628): 2055-10.1126/science.1084125.CrossRefPubMed
2.
H G: Progeria: a form of senilism. Practitioner. 1904, 73: 188-217.
3.
Hennekam RC: Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006, 140 (23): 2603-2624.CrossRefPubMed
4.
Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby K, Astudillo A, Wernerson A, Rodriguez F, Tryggvason K: Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet. 2002, 31 (1): 94-99.PubMed
5.
Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y: DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci. 2006, 119 (Pt 22): 4644-4649. 10.1242/jcs.03263.PubMedCentralCrossRefPubMed
6.
Varela I, Cadinanos J, Pendas AM, Gutierrez-Fernandez A, Folgueras AR, Sanchez LM, Zhou Z, Rodriguez FJ, Stewart CL, Vega JA: Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature. 2005, 437 (7058): 564-568. 10.1038/nature04019.CrossRefPubMed
7.
Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM, Chau PY, Chen DJ: Genomic instability in laminopathy-based premature aging. Nat Med. 2005, 11 (7): 780-785. 10.1038/nm1266.CrossRefPubMed
8.
Fishel R: Genomic instability, mutators, and the development of cancer: is there a role for p53?. J Natl Cancer Inst. 1996, 88 (22): 1608-1609. 10.1093/jnci/88.22.1608.CrossRefPubMed
9.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature. 1998, 396 (6712): 643-649. 10.1038/25292.CrossRefPubMed
10.
11.
Chen Y, Tang Y, Wang MT, Zeng S, Nie D: Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007, 67 (21): 10361-10367. 10.1158/0008-5472.CAN-06-4758.CrossRefPubMed
12.
13.
Fischer AH, Taysavang P, Weber CJ, Wilson KL: Nuclear envelope organization in papillary thyroid carcinoma. Histol Histopathol. 2001, 16 (1): 1-14.PubMed
14.
Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R: Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2004, 101 (24): 8963-8968. 10.1073/pnas.0402943101.PubMedCentralCrossRefPubMed
15.
Scaffidi P, Misteli T: Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med. 2005, 11 (4): 440-445. 10.1038/nm1204.PubMedCentralCrossRefPubMed
16.
Campisi J: Cancer, aging and cellular senescence. In Vivo. 2000, 14 (1): 183-188.PubMed
17.
Wang Y, Perrault AR, Iliakis G: Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint?. Cancer Res. 1997, 57 (9): 1654-1659.PubMed
18.
Kastan MB, Lim DS: The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000, 1 (3): 179-186. 10.1038/35043058.CrossRefPubMed
19.
Moneef MA, Sherwood BT, Bowman KJ, Kockelbergh RC, Symonds RP, Steward WP, Mellon JK, Jones GD: Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer. 2003, 89 (12): 2271-2276. 10.1038/sj.bjc.6601333.PubMedCentralCrossRefPubMed
20.
Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991, 51 (12): 3075-3079.PubMed
21.
Aebi U, Cohn J, Buhle L, Gerace L: The nuclear lamina is a meshwork of intermediate-type filaments. nature. 1986, 323: 560-564. 10.1038/323560a0.CrossRefPubMed
22.
Marino G, Ugalde AP, Salvador-Montoliu N, Varela I, Quiros PM, Cadinanos J, van der Pluijm I, Freije JM, Lopez-Otin C: Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet. 2008, 17 (14): 2196-2211. 10.1093/hmg/ddn120.CrossRefPubMed
23.
Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E: Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007, 21 (11): 1367-1381. 10.1101/gad.1545107.PubMedCentralCrossRefPubMed
24.
Young SG, Fong LG, Michaelis S: Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005, 46 (12): 2531-2558. 10.1194/jlr.R500011-JLR200.CrossRefPubMed
25.
Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS: Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA. 2005, 102 (36): 12879-12884. 10.1073/pnas.0506001102.PubMedCentralCrossRefPubMed
26.
End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001, 61 (1): 131-137.PubMed
27.
Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995, 55 (22): 5302-5309.PubMed
Metadata
Title
Promotion of tumor development in prostate cancer by progerin
Authors
Yong Tang
Yakun Chen
Hongmei Jiang
Daotai Nie
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-47

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Review

PADI4 and tumourigenesis

Primary research

Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells

Primary research

Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR

Primary research

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis

Hypothesis

From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer

Primary research

MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits